This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Fludrocortisone for Sudden Hearing Loss

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified April 2015 by Anh Nguyen-Huynh, Oregon Health and Science University.
Recruitment status was:  Recruiting
Information provided by (Responsible Party):
Anh Nguyen-Huynh, Oregon Health and Science University Identifier:
First received: August 19, 2010
Last updated: April 21, 2015
Last verified: April 2015
The standard of care treatment of sudden hearing loss uses a type of steroid called glucocorticoid. Examples of glucocorticoids are prednisone, methylprednisolone and dexamethasone. Not everybody recovers hearing with glucocorticoid treatment. Fludrocortisone is a different type of steroid called mineralocorticoid. Unlike glucocorticoids, which work by reducing inflammation, mineralocorticoids work by changing salt and fluid balance. In animal studies, fludrocortisone is at least as effective as glucocorticoid in preserving hearing. Fludrocortisone is not approved for the treatment of sudden hearing loss. The purpose of this study is to test whether fludrocortisone can treat sudden hearing loss.

Condition Intervention
Hearing Loss, Sensorineural Drug: Fludrocortisone

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Mineralocorticoid Treatment for Sudden Sensorineural Hearing Loss

Resource links provided by NLM:

Further study details as provided by Anh Nguyen-Huynh, Oregon Health and Science University:

Primary Outcome Measures:
  • Hearing [ Time Frame: At one month ]
    Hearing outcome will be determine by pure-tone and speech audiometry measured at the completion of a one-month course of treatment and compared with pre-treatment test results.

Estimated Enrollment: 20
Study Start Date: August 2012
Estimated Study Completion Date: August 2016
Estimated Primary Completion Date: August 2016 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Fludrocortisone Drug: Fludrocortisone
Fludrocortisone 0.2 mg by mouth daily for 30 days


Ages Eligible for Study:   18 Years to 89 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Age 18 or older
  • Idiopathic sudden sensorineural hearing loss within 3 months
  • Failure to recover hearing with glucocorticoid treatment or inability to tolerate glucocorticoid

Exclusion Criteria:

  • Other diagnosis for the sudden hearing loss
  • Concurrent systemic use of another steroid
  • Hypersensitivity to fludrocortisone
  • Systemic fungal infection
  • Hypertension requiring two or more medications
  • Pitting edema
  • Cardiomegaly
  • Congestive heart failure
  • Electrolyte abnormality
  • Concurrent use of barbiturates, phenytoin, fosphenytoin, rifampin, or rifapentine
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01186185

Contact: Anh Nguyen-Huynh, MD PhD 503-494-8135

United States, Oregon
Oregon Health & Science University Recruiting
Portland, Oregon, United States, 97239
Contact: Anh Nguyen-Huynh    503-260-9192   
Principal Investigator: Anh Nguyen-Huynh, MD PhD         
Sponsors and Collaborators
Oregon Health and Science University
Principal Investigator: Anh Nguyen-Huynh, MD PhD Oregon Health and Science University
  More Information

Responsible Party: Anh Nguyen-Huynh, Assistant Professor, Oregon Health and Science University Identifier: NCT01186185     History of Changes
Other Study ID Numbers: IRB00006240
Study First Received: August 19, 2010
Last Updated: April 21, 2015

Keywords provided by Anh Nguyen-Huynh, Oregon Health and Science University:
hearing loss

Additional relevant MeSH terms:
Hearing Loss
Hearing Loss, Sensorineural
Hearing Disorders
Ear Diseases
Otorhinolaryngologic Diseases
Sensation Disorders
Neurologic Manifestations
Nervous System Diseases
Signs and Symptoms
Anti-Inflammatory Agents
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs processed this record on September 21, 2017